SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis
Published: Wednesday, Jul 17, 2019
Thomas Herzog, MD
A key message from the phase III SOLO-1 trial is that patients with ovarian cancer should be tested for BRCA mutations quickly after diagnosis to inform physicians what treatment will be most effective, explained Thomas Herzog, MD.
... to read the full story